| Literature DB >> 33770132 |
Masayoshi Shinjoh1, Norio Sugaya2, Yoshio Yamaguchi3, Ichiro Ookawara4, Yuji Nakata5, Atsushi Narabayashi6, Munehiro Furuichi1, Naoko Yoshida1, Akinobu Kamei7, Yuu Kuramochi8, Akimichi Shibata9, Motoko Shimoyamada10, Hisataka Nakazaki11, Naohiko Maejima12, Erika Yuasa13, Eriko Araki9, Naonori Maeda14, Takuma Ohnishi15, Mitsuhiro Nishida16, Nobuhiko Taguchi2, Makoto Yoshida17, Kenichiro Tsunematsu18, Meiwa Shibata19, Yasuhiro Hirano20, Shinichiro Sekiguchi1, Chiharu Kawakami21, Keiko Mitamura22, Takao Takahashi1.
Abstract
During influenza epidemics, Japanese clinicians routinely conduct rapid influenza diagnostic tests (RIDTs) in patients with influenza-like illness, and patients with positive test results are treated with anti-influenza drugs within 48 h after the onset of illness. We assessed the vaccine effectiveness (VE) of inactivated influenza vaccine (IIV) in children (6 months-15 years old, N = 4243), using a test-negative case-control design based on the results of RIDTs in the 2018/19 season. The VE against influenza A(H1N1)pdm and A(H3N2) was analyzed separately using an RIDT kit specifically for detecting A(H1N1)pdm09. The adjusted VE against combined influenza A (H1N1pdm and H3N2) and against A(H1N1)pdm09 was 39% (95% confidence interval [CI], 30%-46%) and 74% (95% CI, 39%-89%), respectively. By contrast, the VE against non-A(H1N1)pdm09 influenza A (presumed to be H3N2) was very low at 7%. The adjusted VE for preventing hospitalization was 56% (95% CI, 16%-77%) against influenza A. The VE against A(H1N1)pdm09 was consistently high in our studies. By contrast, the VE against A(H3N2) was low not only in adults but also in children in the 2018/19 season.Entities:
Year: 2021 PMID： 33770132 PMCID： PMC7997015 DOI： 10.1371/journal.pone.0249005
Source DB: PubMed Journal: PLoS One ISSN： 1932-6203 Impact factor: 3.240